| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 9, 2016
LEXINGTON, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Nov 3, 2016Management to host conference call today at 8:30 a.m. EDT
LEXINGTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Oct 27, 2016
LEXINGTON, Mass., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the...
-
Oct 11, 2016Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint AntagonistCA-327, a PD-L1/TIM3 dual antagonist designed and optimized by Aurigene, licensed as the 2nd oral small molecule immuno-oncology development candidate under the Curis Aurigene collaboration
LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...
-
Oct 11, 2016
LEXINGTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates...